Literature DB >> 2283791

Predictive value of fibrin monomers in postoperative deep vein thrombosis.

G Vogel1, E Spanuth.   

Abstract

Intravascular activation of the coagulation system produces disseminated intravascular coagulation or deep vein thrombosis and is characterized by the occurrence of circulating soluble fibrin monomer complexes (FM) in plasma. In order to evaluate the prognostic and diagnostic value of this parameter in 156 patients with fractures of the femur, neck of the femur, tibia, and fibula, and with knee-joint or elective hip surgery, soluble fibrin monomer complexes (FM) were determined using the FM Test from Boehringer Mannheim/Diagnostica STAGO (erythrocyte agglutination test according to Largo). Plasma samples were taken prior to and on the 1st, 2nd, 3rd, 5th, 7th, and 9th postoperative day. Diagnosis of DVT was carried out by 125-I-labelled fibrinogen test in parallel. Positive results were checked by phlebography on the 7th or 9th postoperative day. Positive FM results were obtained in only 26% of patients without DVT. In 34 of 36 patients (94%) with postoperative DVT confirmed by phlebography, on the other hand, elevated FM levels were detected 2-4 days before the 125-I-labelled fibrinogen test gave positive results. The predictive value calculated on the basis of elevated FM levels is 63-73%. These results show that the FM Test allows early detection of a prethrombotic state in the development of postoperative DVT.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2283791     DOI: 10.1007/bf01646548

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  7 in total

1.  Detection of soluble intermediates of the fibrinogen-fibrin conversion using erythrocytes coated with fibrin monomers.

Authors:  R Largo; V Heller; P W Straub
Journal:  Blood       Date:  1976-06       Impact factor: 22.113

2.  Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. The European Fraxiparin Study (EFS) Group.

Authors: 
Journal:  Br J Surg       Date:  1988-11       Impact factor: 6.939

3.  [Prevention of thromboembolism with low-dose heparin].

Authors:  J Kussmann
Journal:  Langenbecks Arch Chir       Date:  1986

4.  Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement.

Authors:  P F Leyvraz; J Richard; F Bachmann; G Van Melle; J M Treyvaud; J J Livio; G Candardjis
Journal:  N Engl J Med       Date:  1983-10-20       Impact factor: 91.245

5.  Fixed combinations of low-molecular weight or unfractionated heparin plus dihydroergotamine in the prevention of postoperative deep vein thrombosis.

Authors:  V V Kakkar; M D Stringer; A R Hedges; C J Parker; D Welzel; V P Ward; R M Sanderson; D Cooper; S Kakkar
Journal:  Am J Surg       Date:  1989-04       Impact factor: 2.565

6.  Heparin inactivation during blood storage: its prevention by blood collection in citric acid, theophylline, adenosine, dipyridamole-C.T.A.D. mixture.

Authors:  G Contant; M Gouault-Heilmann; J L Martinoli
Journal:  Thromb Res       Date:  1983-07-15       Impact factor: 3.944

7.  Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement.

Authors:  A Planes; N Vochelle; F Mazas; C Mansat; J Zucman; A Landais; J C Pascariello; D Weill; J Butel
Journal:  Thromb Haemost       Date:  1988-12-22       Impact factor: 5.249

  7 in total
  2 in total

Review 1.  From Classical Laboratory Parameters to Novel Biomarkers for the Diagnosis of Venous Thrombosis.

Authors:  Larisa Anghel; Radu Sascău; Rodica Radu; Cristian Stătescu
Journal:  Int J Mol Sci       Date:  2020-03-11       Impact factor: 5.923

2.  Novel Biomarkers Associated with Deep Venous Thrombosis: A Comprehensive Review.

Authors:  Dawn M Barnes; Thomas W Wakefield; John E Rectenwald
Journal:  Biomark Insights       Date:  2008-01-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.